[Comparative effectiveness of lotensin and capoten in patients with chronic cardiac failure].

Author: LiV V, SuvorovaS S, TimofeevaN Iu, ZadionchenkoV S

Paper Details 
Original Abstract of the Article :
AIM: To compare clinical response to captopril (capoten) vs benazepril (lotensin) in patients with chronic cardiac failure (CCF) as well as their influence on central hemodynamics, some indices of platelet hemostasis, myocardial ischemia degree, exercise tolerance. MATERIAL AND METHODS: 54 patients...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/12793140

データ提供:米国国立医学図書館(NLM)

A Heartfelt Battle: Comparing Lotensin and Capoten in Chronic Cardiac Failure

Chronic cardiac failure, a debilitating condition that weakens the heart's ability to pump blood efficiently, is a formidable foe in the world of cardiovascular disease. This study seeks to compare the effectiveness of two medications, captopril (Capoten) and benazepril (Lotensin), in treating patients with chronic cardiac failure. The researchers meticulously recruited 54 patients, dividing them into two groups – one receiving captopril and the other receiving benazepril. They then carefully monitored the patients' clinical response, analyzing key indicators such as functional class, exercise tolerance, platelet aggregation, and the frequency of arrhythmias and myocardial ischemia episodes.

A Journey of Improvement: Analyzing the Effectiveness of Both Medications

Both captopril and benazepril demonstrated positive effects, improving functional class, exercise tolerance, and platelet aggregation while reducing the frequency of arrhythmias and myocardial ischemia episodes. However, lotensin emerged as a potential frontrunner, leading to further improvements in clinical and laboratory indices over the long term. Importantly, lotensin was more effective in reducing episodes of ST expression on ECG and episodes of painless myocardial ischemia, highlighting a potentially significant advantage in managing specific cardiac complications.

A Path to Better Heart Health: Navigating Treatment Choices

This study offers valuable insights for healthcare professionals seeking to optimize treatment for patients with chronic cardiac failure. By carefully evaluating the relative benefits of captopril and lotensin, clinicians can make informed decisions tailored to each patient's unique needs. It's a reminder that in the challenging landscape of cardiovascular disease, finding the right path for each patient is crucial for achieving the best possible outcomes.

Dr. Camel's Conclusion

This research, much like a caravan crossing a vast desert, offers a roadmap for navigating the complexities of chronic cardiac failure treatment. It highlights the importance of tailored treatment strategies and offers hope for better outcomes for patients with this challenging condition.
Date :
  1. Date Completed 2003-08-01
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

12793140

DOI: Digital Object Identifier

12793140

Related Literature

SNS
PICO Info
in preparation
Languages

Russian

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.